Summing up the good, the bad and the ugly for the past year Genetic Engineering & Biotechnology News recently published a retrospective on 2017 clinical trial failures written by GEN contributor Alex Philippidis. Philippidis highlights in particular the increasing number of studies in which cancer immunotherapies have come up short, reflecting the scramble among drug developers to gain competitive advantage in the increasingly crowded immuno-oncology category. Read the whole article here https://www.genengnews.com/the-lists/unlucky-13-top-clinical-trial-failures-of-2017/77901028